WO2022211396A1 - Composition pharmaceutique incluant un extrait de salvia plebeia r. br. ou un composé dérivé de celui-ci en tant que principe actif pour la prévention ou le traitement de la dystrophie musculaire - Google Patents

Composition pharmaceutique incluant un extrait de salvia plebeia r. br. ou un composé dérivé de celui-ci en tant que principe actif pour la prévention ou le traitement de la dystrophie musculaire Download PDF

Info

Publication number
WO2022211396A1
WO2022211396A1 PCT/KR2022/004284 KR2022004284W WO2022211396A1 WO 2022211396 A1 WO2022211396 A1 WO 2022211396A1 KR 2022004284 W KR2022004284 W KR 2022004284W WO 2022211396 A1 WO2022211396 A1 WO 2022211396A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
baeam
chazugi
atrophy
muscle
Prior art date
Application number
PCT/KR2022/004284
Other languages
English (en)
Korean (ko)
Inventor
김철영
김영미
이윤정
김지훈
송재숙
김재용
Original Assignee
한양대학교 에리카산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한양대학교 에리카산학협력단 filed Critical 한양대학교 에리카산학협력단
Publication of WO2022211396A1 publication Critical patent/WO2022211396A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/30—Other Organic compounds

Definitions

  • the present invention relates to a pharmaceutical composition for preventing or treating muscular atrophy comprising an extract of Salvia plebeia R. Br. or a compound derived therefrom, rosmarinic acid and/or hispidulin as an active ingredient. it's about
  • muscle mass loss There are about 460 muscles in our body, and the muscles play an important role in body functions such as maintaining posture and balance or moving. In addition, muscles are the largest organs, accounting for 45-55% of body weight, and play an important role in energy metabolism and thermogenesis. When these muscle masses decrease due to various causes, a vicious cycle of musculoskeletal degeneration begins based on the weakening of muscle strength for physical activity. A decrease in walking speed and weakness in grip strength are the main symptoms and indicators of muscle mass loss, which may additionally lead to falls, fractures, joint damage, metabolic disorders, and cardiovascular diseases.
  • Decreased muscle mass can occur naturally according to the aging of the body, and is caused by muscle non-use or lack of exercise, or other pathological conditions (cachexia, sepsis, starvation, chemotherapy, excessive exposure to stress hormones, etc.) ) may be a secondary cause. This can be bundled into muscle cell atrophy due to anti-anabolic and catabolic action of type 1 and type 2 muscle fibers.
  • a natural product-derived biological material that can help maintain muscle mass even in a state that induces a decrease in muscle fiber proteins can be used.
  • Glucocorticoids act to inhibit the PI3K/Akt/mTOR pathway as an anti-anabolic action, which inhibits the activities of downstream effectors 4E-BP1 and p70S6K, such as eIF4G (Eukaryotic translation initiation factor 4 G) and eIF4E (Eukaryotic translation initiation factor 4 E). This inhibits the mRNA translation process for protein synthesis, resulting in inhibition of muscle fiber synthesis and muscle fiber atrophy due to protein degradation.
  • eIF4G Eukaryotic translation initiation factor 4 G
  • eIF4E Eukaryotic translation initiation factor 4 E
  • Glucocorticoids not only inhibit muscle synthesis, but also break down proteins to induce muscle atrophy.
  • the gene that induces muscle atrophy is Atrogene (Atrogin-1/MAFbx). , MuRF-1, etc.), the gene induces degradation of proteins represented by the ubiquitin/proteasome system.
  • Salvia plebeia R. Br. is a biennial plant of the Lamiaceae family. It is called baeba cabbage because its leaves are wrinkled and look like gombo cabbage and snake scales. It is recorded as Yeochicho ( ⁇ ) because it is a grass with fragrant branches on the bonchogangmok ( ⁇ ). Leaves are 3-8 cm long, clustered at the root, spread over the ground, opposite each other, and have dull sawtooths on the edge of the leaf, and sometimes there are fine hairs on the front and back, so the petiole has a long petiole. When they are young, they are crumpled and flat, attached to the ground, and overwinter. The whole grass is medicinal. It has the effects of blood volume, dihydration, detoxification, and insecticide, so it is used to treat blood loss, hematemesis, hematuria, sore throat, tooth ulcers, etc.
  • Korean Patent Registration No. 10-1794567 discloses allergic asthma inhibitory activity of baeam chazugi extract or fraction
  • Korean Patent No. 10-1702120 discloses gout prevention or Although the therapeutic effect is disclosed, the preventive or therapeutic effect of baeam chazugi extract or a compound derived therefrom is not known.
  • the present inventors have intensively studied ingredients derived from natural products that can alleviate skeletal muscle reduction, and as a result, the extract of Baeam chazugi and its derived compounds rosmarinic acid and / or hispidulin ), it was confirmed that the preventive or therapeutic effect of the composition containing the muscle atrophy is excellent, and completed the present invention.
  • the technical problem to be achieved by the present invention is to provide a pharmaceutical composition for preventing or treating muscle atrophy comprising an extract of baeam chazugi as an active ingredient.
  • Another object of the present invention is to provide a health functional food composition for preventing or improving muscle loss comprising the extract of Baeam chazugi as an active ingredient.
  • Another object of the present invention is to provide a method for preparing the baeam chazugi extract.
  • the present invention provides a pharmaceutical composition for preventing or treating muscle atrophy comprising an extract of baeam chazugi as an active ingredient.
  • the present invention provides a method for preventing or treating muscle atrophy comprising administering the baeam chazugi extract to an individual.
  • the present invention provides a use of the baeam chazugi extract for the preparation of a medicament for the prevention or treatment of muscle atrophy.
  • the baeam chazugi extract is water (H 2 O), C 1 to C 4 lower alcohol, n-hexane, ethyl acetate, acetone, butyl acetate, 1,3-butylene glycol, It may be extracted with one or more solvents selected from the group consisting of methylene chloride, and a mixed solvent thereof, and preferably 50% ethanol as a solvent.
  • the composition may have a preventive and/or ameliorating effect on the reduction of muscle fiber bundles, inflammatory cell infiltration and local fibrosis of the muscle.
  • the muscle atrophy is sarcopenia, insoluble muscle atrophy, muscle atrophy due to absence of mechanical stimulation, denervational atrophy, drug-induced muscular atrophy (Drug induced atrophy), nutritional deficiency muscle atrophy (Malnutritional atrophy), and may be at least one selected from the group consisting of muscular dystrophy (Muscular dystrophy).
  • the composition may reduce the expression of one or more selected from the group consisting of MuRF-1 and Atrogin-1/MAFbx in myotube cells.
  • the composition may increase phosphorylation of p70S6K in myotube cells.
  • the baeam chazugi extract may include rosmarinic acid represented by the following [Formula 1] as an active ingredient.
  • the baeam chazugi extract may include hispidulin represented by the following [Formula 2] as an active ingredient.
  • the present invention provides a health functional food composition for preventing or improving muscle loss comprising a baeam chazugi extract as an active ingredient.
  • the baeam chazugi extract is water (H 2 O), C 1 to C 4 lower alcohol, n-hexane, ethyl acetate, acetone, butyl acetate, 1,3-butylene glycol, It may be extracted with one or more solvents selected from the group consisting of methylene chloride, and a mixed solvent thereof, and preferably 50% ethanol as a solvent.
  • the muscle loss may mean including a qualitative loss due to a decrease in the diameter of myotube cells, and may include both a quantitative loss due to a decrease in the number of myotube cells.
  • the composition may reduce the expression of one or more selected from the group consisting of MuRF-1 and Atrogin-1/MAFbx in myotube cells.
  • the composition may increase the phosphorylation of Akt in myotube cells.
  • the baeam chazugi extract may include rosmarinic acid represented by the above [Formula 1] as an active ingredient.
  • the baeam chazugi extract may include hispidulin represented by the above [Formula 2] as an active ingredient.
  • the present invention provides a method for preparing a composition for preventing, improving or treating muscular atrophy, comprising the following steps.
  • step (b) after the step (b), it may further include a step of lyophilizing after concentrating the extracted extract.
  • the muscle atrophy is sarcopenia, insoluble muscle atrophy, muscle atrophy caused by the absence of mechanical stimulation, denervational atrophy, drug-induced muscular atrophy ( Drug induced atrophy), nutritional deficiency muscle atrophy (Malnutritional atrophy), and may be at least one selected from the group consisting of muscular dystrophy (Muscular dystrophy).
  • the present invention provides a pharmaceutical composition for preventing or treating muscular atrophy comprising rosmarinic acid represented by Formula 1 and/or hispidulin represented by Formula 2 as active ingredients.
  • the present invention provides a method for preventing or treating muscular atrophy comprising administering to a subject rosmarinic acid represented by Formula 1 and/or hispidulin represented by Formula 2 above.
  • the present invention provides the use of rosmarinic acid represented by the above formula (1) and/or hispidulin represented by the above formula (2) for the manufacture of a medicament for the prevention or treatment of muscular atrophy.
  • the subject may have a genetic predisposition to muscular dystrophy or a patient with amyotrophic disease.
  • the prophylactic or therapeutic method may be to additionally perform one or more of the following steps (1) to (6) of the subject before and/or after the administration:
  • the present invention relates to a composition for preventing, improving or treating muscle atrophy, which includes an extract of Salvia plebeia R. Br. or a compound derived therefrom, rosmarinic acid and/or hispidulin as an active ingredient.
  • the extract or a compound derived therefrom inhibits the expression of a muscle fiber atrophy-related protein, increases the activity of a protein involved in muscle protein synthesis to prevent a decrease in muscle fiber thickness, and has almost no side effects and high safety because it is derived from a natural product, It can be usefully used to prevent or treat muscle atrophy.
  • Figure 2 is (A) Cytotoxicity of myotube cells C2C12 cells in the control group of the present invention, a negative control group treated with dexamethasone to induce muscle atrophy, a Baeam chazugi extract treated group, and a dexamethasone and Baeam chazugi extract treated group. , (B) staining of myosin heavy chain (MHC) (C) area of myosin heavy chain, (D) a change in cell thickness and (E) a change in Fusin index is compared.
  • MHC myosin heavy chain
  • C area of myosin heavy chain
  • D a change in cell thickness
  • E a change in Fusin index is compared.
  • Figure 3 is a control group of the present invention, negative control group, baeam chazugi extract treatment group, dexamethasone and baeam chazugi treated group
  • A western blot results
  • B myosin heavy chain expression level
  • C Atrogin-1 / MAFbx
  • D MuRF-1
  • E shows the phosphorylation degree of Akt.
  • FIG. 4 is a comparison of the thickness change of myotube C2C12 cells in the control group of the present invention, a negative control group treated with dexamethasone to induce muscle atrophy, a dexamethasone and rosmarinic acid treatment group, and a dexamethasone and hispidulin treatment group.
  • the present inventors have intensively researched on Salvia plebeia R. Br. extract or a compound derived thereof, rosmarinic acid and / or hispidulin, as a result of intensive study, the hypertrophy-related protein of the extract or compound
  • the present invention was completed by confirming the alleviation effect of increasing expression and decreasing skeletal muscle.
  • the diameter of myotube increases as a result of treatment with the extract or compound, and phosphorylation and/or expression of a protein that promotes muscle protein synthesis It was confirmed that the degree of recovery was restored.
  • the present invention provides a pharmaceutical composition for preventing or treating muscular atrophy comprising the baeam chazugi extract or a compound derived therefrom as an active ingredient.
  • extract refers to a liquid component obtained by immersing a target substance in various solvents and then extracting it for a certain period of time at room temperature or heated state, a solid obtained by removing the solvent from the liquid component, etc. means the result of In addition, in addition to the result, it can be comprehensively interpreted as including all of the dilutions of the results, their concentrates, their preparations, and their purified products.
  • the extract can be extracted from various organs of natural, hybrid, and variegated plants as Salvia plebeia R. Br. extract, for example, roots, above-ground parts, stems, leaves, petals, flowers. It can be extracted from buds, fruit body, fruit skin as well as plant tissue culture.
  • the baeam chazugi extract of the present invention can be extracted according to a conventional method known in the art for obtaining an extract from a natural product, that is, using a conventional solvent under conditions of conventional temperature and pressure.
  • the baeam chazugi extract is selected from the group consisting of water, alcohol having 1 to 4 carbon atoms, n-hexane, ethyl acetate, acetone, butyl acetate, 1,3-butylene glycol, methylene chloride, and a mixed solvent thereof. It can be extracted using one or more solvents, but is not particularly limited as long as an extract having a preventive or therapeutic effect on muscular atrophy can be obtained.
  • the extraction may be performed using a mixed solvent of water and an alcohol having 1 to 4 carbon atoms.
  • water and alcohol may be mixed in a volume ratio of 1:5 to 1:1, but more preferably It can be extracted using 50% ethanol.
  • the extraction efficiency of the effective substance having the effect of improving the muscular atrophy of Bangui may vary.
  • the method for obtaining the extract is also cold-chilled extraction method for extracting at room temperature of 10 to 25°C, hot water extraction method for extraction by heating to 40 to 100°C, ultrasound, as long as an extract having a preventive or therapeutic effect of muscle atrophy can be obtained It may be an ultrasonic extraction method of extracting by adding a reflux extraction method using a reflux condenser, but is not particularly limited thereto.
  • the prepared extract may then be filtered or concentrated or dried to remove the solvent, and both filtration, concentration and drying may be performed, and the filtration, concentration or drying process may be performed several times.
  • the filtration may be performed using a filter paper or a reduced pressure filter
  • the concentration may be performed by a vacuum concentrator
  • the drying may be performed by a spray drying method, a freeze drying method, and the like, but is not particularly limited thereto.
  • the extract extracted with the solvent may then be further subjected to a fractionation process with a solvent selected from the group consisting of butanol, n-hexane, methylene chloride, acetone, ethyl acetate, ethyl ether, chloroform, water, or mixtures thereof. , but not limited thereto.
  • a solvent selected from the group consisting of butanol, n-hexane, methylene chloride, acetone, ethyl acetate, ethyl ether, chloroform, water, or mixtures thereof. , but not limited thereto.
  • the present invention is a baeam chazugi grinding step of (a) grinding the dried baeam chazugi to prepare baeam chazugi powder; (b) extracting the pulverized baeam chazugi powder with a solvent of 50% ethanol; and (c) concentrating the extract extracted therefrom and then freeze-drying.
  • muscle atrophy refers to a state in which muscle mass is reduced due to atrophy of muscle or a decrease in the number or cross-sectional area of muscle fibers.
  • muscle atrophy is accompanied by physiological, histochemical, and biochemical changes due to a decrease in muscle protein, and may cause intrinsic dysfunction of skeletal muscle.
  • Fidulin may be used for the purpose of maintaining and preserving the intrinsic function of skeletal muscle resulting from muscle atrophy from the function of increasing the activity of the muscle fiber and protecting the muscle fiber.
  • the muscle atrophy is a non-limiting example, and the muscle atrophy is sarcopenia, insoluble muscle atrophy (Disuse atrophy), muscle atrophy due to absence of mechanical stimulation, denervational atrophy, drug-induced muscle It includes atrophy (Drug induced atrophy), malnutritional atrophy (Malnutritional atrophy), muscular dystrophy (Muscular dystrophy) and the like.
  • the insoluble muscle atrophy includes a decrease in the thickness of the muscle due to activity restrictions due to aging or disease, long bed life, cast or plaster fixation (Gips), etc., peripheral nerve damage, cancer, sepsis, etc. It is accompanied by long-term bed rest and aging processes as well as clinical diseases.
  • the absence of mechanical stimulation and loss of innervation muscle atrophy cause a quantitative decrease and dysfunction of mitochondria, and increase mitochondrial reactive oxygen species (ROS) production, resulting in apoptosis of muscle cells by oxidative damage ( muscle atrophy due to apoptosis).
  • ROS mitochondrial reactive oxygen species
  • the muscular dystrophy is characterized by muscle atrophy and muscle weakness caused by the absence of dystrophin-glycoprotein complex formation, which is a component of the striated muscle plasma membrane due to gene mutation.
  • cortisol is a substance that can be secreted in the body due to various acute stresses, and serves to supply energy against stress, but also causes muscle atrophy of the body according to its mechanism.
  • synthetic corticosteroids may cause steroid induced atrophy, muscle parenchymal damage, etc. as an adverse reaction.
  • composition for preventing, improving or treating muscle atrophy comprising the baeam chazugi extract of the present invention or a compound derived therefrom increases the thickness or mass of muscle fibers beyond indirectly preventing muscle loss by reducing the expression of inflammatory cytokines, By inhibiting the induction of muscle atrophy by protein degradation, it is possible to directly prevent, improve or treat the aforementioned muscular atrophy.
  • prevention refers to any action that inhibits or delays the onset of muscle atrophy by administration of the composition according to the present invention
  • treatment refers to suspected and onset of muscular atrophy by administration of the pharmaceutical composition. It refers to any action in which the symptoms of an individual are improved or changed to a beneficial effect.
  • the term "pharmaceutical composition” means one prepared for the purpose of preventing or treating a disease, and each may be formulated in various forms according to a conventional method and used. For example, it may be formulated in oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, and syrups, and may be formulated in the form of external preparations, suppositories, and sterile injection solutions.
  • “included as an active ingredient” means that the ingredient is included in an amount necessary or sufficient to realize a desired biological effect.
  • the amount can be determined taking into account other non-toxic factors and may vary depending on various factors, such as, for example, the disease or condition being treated, the form of the composition being administered, the size of the subject, or the severity of the disease or condition.
  • a person of ordinary skill in the art to which the present invention pertains can empirically determine the effective amount of an individual composition without undue experimentation.
  • composition of the present invention may include one or more pharmaceutically acceptable carriers in addition to the active ingredients described above according to each formulation.
  • the pharmaceutically acceptable carrier may be saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, and a mixture of one or more of these components, if necessary, antioxidants, buffers, bacteriostats It may further include other conventional additives, such as.
  • diluents, dispersants, surfactants, binders and lubricants may be additionally added to form an injectable formulation such as an aqueous solution, suspension, emulsion, etc., pills, capsules, granules or tablets.
  • it may be preferably formulated according to each disease or component using an appropriate method in the art or a method disclosed in Remington's Pharmaceutical Science (Mack Publishing Company, Easton PA).
  • composition of the present invention may be administered orally or parenterally in a pharmaceutically effective amount according to a desired method
  • pharmaceutically effective amount means a disease with a reasonable benefit/risk ratio applicable to medical treatment. It means an amount sufficient to treat the drug and does not cause side effects, and the effective dose level includes the patient's health condition, severity, drug activity, drug sensitivity, administration method, administration time, administration route, and excretion rate; It may be determined according to factors including the duration of treatment, combination or concurrent drugs, and other factors well known in the medical field.
  • the term "individual” may be a mammal, such as a rat, livestock, mouse, or human, preferably a human.
  • compositions of the present invention may be formulated in various forms for administration to a subject, and a representative formulation for parenteral administration is an injection formulation, preferably an isotonic aqueous solution or suspension.
  • Formulations for injection may be prepared according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. For example, each component may be dissolved in saline or buffer to be formulated for injection.
  • formulations for oral administration include, for example, ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups and wafers.
  • the tablet may contain a binder such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidine, and optionally starch, agar, alginic acid or its It may further include disintegrating agents such as sodium salts, absorbents, coloring agents, flavoring agents and/or sweetening agents.
  • the formulation may be prepared by conventional mixing, granulating or coating methods.
  • the pharmaceutical composition of the present invention is a binder, lubricant, disintegrant, colorant, preservative, sweetening agent, flavoring agent, stabilizer, diluent, preservative, wetting agent, emulsification accelerator, auxiliaries such as salts or buffers for regulating osmotic pressure and others It may further include a therapeutically useful substance, and may be formulated according to a conventional method.
  • the pharmaceutical composition according to the present invention may be administered through several routes including oral, transdermal, subcutaneous, intravenous or intramuscular, and the dosage of the active ingredient may vary depending on the route of administration, age, sex, weight, and severity of the patient. It may be appropriately selected according to several factors.
  • the composition of the present invention may be administered in parallel with a known compound capable of enhancing the desired effect.
  • the pharmaceutical composition according to the present invention may be administered orally or parenterally, such as intravenously, subcutaneously, intranasally or intraperitoneally, to humans and animals.
  • Oral administration also includes sublingual application.
  • Parenteral administration includes injection methods such as subcutaneous injection, intramuscular injection and intravenous injection and drip method.
  • the present invention can be used as a health functional food composition for preventing or improving muscle atrophy and/or muscle loss comprising the baeam chazugi extract or a compound derived therefrom, rosmarinic acid and/or hispidulin as active ingredients.
  • the term "health functional food composition” means that the baeam tea extract or a compound derived therefrom is added to food materials such as beverages, teas, spices, gum, confectionery, etc., or food prepared by encapsulation, powdering, suspension, etc. As such, it means that it brings a specific health effect when ingested, but unlike general drugs, it has the advantage that there are no side effects that may occur when taking the drug for a long period of time using food as a raw material.
  • the health functional food composition is selected from meat, grains, caffeinated beverages, general drinks, chocolate, breads, snacks, confectionery, pizza, jelly, noodles, gums, ice cream, alcoholic beverages, alcohol, vitamin complexes and other health supplements. may be any one of
  • the baeam chazugi extract of the present invention contains rosmarinic acid and hispidulin (FIG. 1).
  • the C2C12 mouse myoblast cells used in this experiment were provided by the Korea Research Institute of Bioscience and Biotechnology Biological Resources Center, and Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 ⁇ g/mL streptomycin. was used as a growth medium and incubated under 5% CO 2 , 37 °C conditions.
  • C2C12 myoblasts were dispensed in a 12 well plate and cultured. When the cell density reached 80-85%, use a differentiation medium (DMEM containing 2% horse serum, 100 U/mL penicillin, and 100 ⁇ g/mL streptomycin) every two days. They were replaced with fresh medium and differentiated for 6 days.
  • DMEM Dulbecco's modified Eagle's medium
  • Dexamethasone induces muscle atrophy by inhibiting muscle synthesis and causing protein degradation.
  • the C2C12 cells induced to differentiate in Example 2-1 were treated with dexamethasone to induce muscle atrophy, and the muscle atrophy induced cells were treated with embryo cancer.
  • the tea extract was treated. Specific experimental conditions are as follows.
  • a control group was prepared by treating C2C12 myotube cells that had completed differentiation in a differentiation medium supplemented with only 1% Penicillin for 24 hours.
  • the dexamethasone-treated group was prepared by preparing a differentiation medium supplemented with 1% Penicillin to have a 10 ⁇ M Dexamethasone composition, and then treating the differentiated C2C12 myotube cells for 24 hours.
  • Dexamethasone and Baeam chazugi extract treated group were prepared by additionally treating Baeam chazugi extract with a composition of 1, 5, and 10 ⁇ g/mL for 24 hours under the same conditions as the negative control of (2).
  • C2C12 myotube cells were simultaneously treated with the baeam chazugi extract at concentrations of 1, 5, and 10 ⁇ g/ml and 10 ⁇ M dexamethasone. After 24 hours, cell viability was measured using the CCK-8 kit.
  • Example 2-2 each control and experimental group treated with the sample for 24 hours were immunofluorescently stained with myosin heavy chain (MyHC), and the results were visualized in green, and the cell nuclei labeled with Hoechst33342 were visualized in blue. This was photographed using JuLiomated, an automated cell imaging system, and analyzed using ImageJ. The thickness of each cell after imaging was measured by 50 per cell group and the average was obtained. After analyzing the number of multinucleated myotube cells, the total number of cells was applied to determine the relative multinucleated- The number of MHC-positive myotubes (MHC-positive myotubes) was calculated. Each experiment was repeated three times.
  • MyHC myosin heavy chain
  • the myosin heavy chain (MyHC) positive area, the cell diameter, and the fusion index of C2C12 myotube were decreased by dexamethasone treatment, but it was improved by the Baeam chazugi extract (Table 3, Figure 2 (B)) - Fig. 2(E)).
  • the area of the myosin heavy chain stained in C2C12 myotube cells in the dexamethasone 10 ⁇ M administration group was reduced by 13% (p ⁇ 0.01), and the thickness was 27% (p ⁇ 0.005) compared to the control group, which is a group administered with the basic differentiation medium. , the fusion index decreased by 28% (p ⁇ 0.005).
  • the area of the myosin heavy chain of C2C12 myotube cells was 18.4% (p ⁇ 0.005), and the thickness was 30.1% ( p ⁇ 0.005), the fusion index increased by 34.7% (p ⁇ 0.005). Therefore, it was confirmed that the baeam chazugi extract of the present invention showed a significant recovery rate in the dexamethasone-induced muscle atrophy model.
  • Example 2-2 MyHC, Atrogin-1/MAFbx, MuRF1, Akt, and p-Akt proteins acting on the pathways of muscle atrophy/synthesis in each of the control and experimental groups treated for 24 hours were subjected to Western blotting (Western blotting). blotting) was used.
  • MyHC myosin heavy chain
  • MuRF1 Akt
  • p-Akt Akt
  • p-Akt Akt
  • Table 4 The expression levels of myosin heavy chain (MyHC), Atrogin-1/MAFbx, MuRF1, Akt, and p-Akt in the control group and the experimental group are shown in Table 4 below.
  • MyHC myosin heavy chain
  • the phosphorylation degree of Akt (p-Akt/t-Akt) was increased by 33.3 times by the treatment of Baeam chazugi extract. Therefore, it was confirmed that the baeam chazugi extract of the present invention improved the atrophy of muscle cells caused by dexamethasone and inhibited the activation of the muscle atrophy factor.
  • Example 3 in vitro Confirmation of the prevention, improvement, or therapeutic effect of a compound derived from Baeam chazugi in
  • dexamethasone was treated to the C2C12 cells induced in the differentiation in Example 2-1 to induce muscle atrophy, and the muscle atrophy-induced cells were treated with dexamethasone. It was treated with rosmarinic acid or hispidulin, a compound derived from chazugi extract. Specific experimental conditions are as follows.
  • a control group was prepared by treating C2C12 myotube cells that had completed differentiation in a differentiation medium supplemented with only 1% Penicillin for 48 hours.
  • the dexamethasone-treated group was prepared by preparing a differentiation medium supplemented with 1% Penicillin to have a 1 ⁇ M Dexamethasone composition, and then treating the differentiation medium with C2C12 for 48 hours.
  • Dexmethasone and rosmarinic acid treatment group were prepared by additionally treating for 48 hours with a composition of 30 ⁇ M rosmarinic acid under the same conditions as the negative control group of (2).
  • Dexmethasone and hispidulin treated group were prepared by additionally treating with a composition of 30 ⁇ M rosmarinic acid for 48 hours under the same conditions as the negative control group in (2).
  • Example 3-1 each of the control and experimental groups treated with the sample for 48 hours was photographed using the JuLi TM Stage, an automated cell imaging system, and the thickness of each cell that was photographed was measured using ImageJ, a cell processing program. 50 measurements were taken per group, the mean and standard error were calculated, and the data were organized (Table 5). Each experiment was repeated three times.
  • control Dex treatment group Dex + rosmarinic acid Dex + Hispidulin Relative thickness of C2C12 myotube cells (% of control) 100% 77.4% 100.6% 104.3%
  • the thickness of C2C12 myotube cells was reduced by 22.6% in the dexamethasone 1 ⁇ M administration group compared to the control group, which is the basal differentiation medium administration group.
  • the thickness of C2C12 myotube cells increased by 23.2% in the group additionally administered with 30 ⁇ M of rosmarinic acid compared to the negative control group administered with dexamethasone in the basal differentiation medium.
  • the thickness of C2C12 myotube cells increased by 26.9% in the group additionally administered hispidulin 30 ⁇ M compared to the negative control group administered with dexamethasone in the basal differentiation medium.
  • the present invention confirmed the effect of reducing the expression of muscle atrophy-related proteins of baeam chazugi extract and its derived rosmarinic acid and hispidulin, and increasing the activity of muscle protein synthesis-related proteins, prevention or treatment of natural-derived muscular atrophy diseases It is expected to be usefully used in pharmaceuticals, quasi-drugs, cosmetic materials, and functional food materials.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition comprenant un extrait de Salvia plebeia R. Br. ou son composé dérivé acide rosmarinique et/ou hispiduline en tant que principe actif pour prévenir, pallier ou traiter la dystrophie musculaire. L'extrait ou le composé dérivé de celui-ci inhibe l'expression d'une protéine liée à la dystrophie musculaire et augmente l'activité d'une protéine impliquée dans la synthèse de protéines musculaires, ce qui permet d'éviter la diminution de l'épaisseur des fibres musculaires. Du fait que l'extrait ou les composés sont dérivés d'un produit naturel, ils n'ont pratiquement pas d'effets secondaires et sont très sûrs, ce qui permet de trouver des applications avantageuses dans la prévention ou le traitement de la dystrophie musculaire.
PCT/KR2022/004284 2021-04-01 2022-03-28 Composition pharmaceutique incluant un extrait de salvia plebeia r. br. ou un composé dérivé de celui-ci en tant que principe actif pour la prévention ou le traitement de la dystrophie musculaire WO2022211396A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020210042450A KR102605187B1 (ko) 2021-04-01 2021-04-01 배암차즈기 추출물 또는 이의 유래 화합물을 유효성분으로 포함하는 근위축 예방 또는 치료용 약학적 조성물
KR10-2021-0042450 2021-04-01

Publications (1)

Publication Number Publication Date
WO2022211396A1 true WO2022211396A1 (fr) 2022-10-06

Family

ID=83456450

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/004284 WO2022211396A1 (fr) 2021-04-01 2022-03-28 Composition pharmaceutique incluant un extrait de salvia plebeia r. br. ou un composé dérivé de celui-ci en tant que principe actif pour la prévention ou le traitement de la dystrophie musculaire

Country Status (2)

Country Link
KR (1) KR102605187B1 (fr)
WO (1) WO2022211396A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009256282A (ja) * 2008-04-21 2009-11-05 Nagase & Co Ltd 抗ａｌｓ剤
US20120196929A1 (en) * 2009-07-31 2012-08-02 Institut De Recherche Pour Le Developpement Use of Rosmarinic Acid and the Derivaties Thereof to Treat Ciguatera
KR20130129868A (ko) * 2012-05-21 2013-11-29 한국생명공학연구원 곰보배추의 추출물 또는 이의 분획물을 유효성분으로 포함하는, stat3 매개 질환의 예방 또는 치료용 약학적 조성물
KR20200104749A (ko) * 2019-02-27 2020-09-04 종근당건강 주식회사 살비아(세이지) 추출물을 함유하는 근육질환의 예방 또는 치료용 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101794567B1 (ko) 2015-06-11 2017-11-07 주식회사 케이티앤지 곰보배추 특정 조추출물 또는 이로부터 분리된 정제 분획물을 유효성분으로 포함하는 호흡기염증 질환의 예방 또는 치료용 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009256282A (ja) * 2008-04-21 2009-11-05 Nagase & Co Ltd 抗ａｌｓ剤
US20120196929A1 (en) * 2009-07-31 2012-08-02 Institut De Recherche Pour Le Developpement Use of Rosmarinic Acid and the Derivaties Thereof to Treat Ciguatera
KR20130129868A (ko) * 2012-05-21 2013-11-29 한국생명공학연구원 곰보배추의 추출물 또는 이의 분획물을 유효성분으로 포함하는, stat3 매개 질환의 예방 또는 치료용 약학적 조성물
KR20200104749A (ko) * 2019-02-27 2020-09-04 종근당건강 주식회사 살비아(세이지) 추출물을 함유하는 근육질환의 예방 또는 치료용 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
30 October 2016 (2016-10-30), SHIN, HAN JAE;GWAK, HYO MIN;JANG, MI;PARK, SI HWAN;MIN, HYE JEONG;LEE, JEONG MIN;LEE, MOON YONG;KIM, JONG HAN;KIM, SUNG WON;HAN, C: "Anti-Inflammatory Activity of Three Kinds of Salvia and Its Active Compounds", XP053036913 *
GHASEMZADEH RAHBARDAR MAHBOOBEH; HOSSEINZADEH HOSSEIN: "Effects of rosmarinic acid on nervous system disorders: an updated review", NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, SPRINGER, DE, vol. 393, no. 10, 28 July 2020 (2020-07-28), DE , pages 1779 - 1795, XP037225500, ISSN: 0028-1298, DOI: 10.1007/s00210-020-01935-w *

Also Published As

Publication number Publication date
KR102605187B1 (ko) 2023-11-23
KR20220136604A (ko) 2022-10-11

Similar Documents

Publication Publication Date Title
WO2010058926A2 (fr) Composition pharmaceutique contenant un extrait de gingembre ou du shogaol
WO2013089449A1 (fr) Composition cosmétique contenant la pellicule biologique d'escargots nourris avec du ginseng rouge et procédé de fabrication de cette composition
WO2017014502A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies médiées par il-6 comprenant un extrait de fleur de rosa rugosa en tant que substance active
WO2016080691A1 (fr) Composition pharmaceutique comprenant des extraits de symplococs chinesis et astragalus membranaceus pour prévenir et traiter l'arthrite, et son procédé de préparation
WO2018208128A1 (fr) Composition pharmaceutique comprenant de la tilianine en tant que principe actif pour le traitement prophylactique ou thérapeutique de la maladie de parkinson
WO2020040432A1 (fr) Composition pharmaceutique pour prévenir ou traiter des maladies musculaires, contenant un extrait de baie de ginseng en tant que principe actif
WO2017183902A1 (fr) Composition contenant des extraits de artemisia capillaris, sanguisorba officinalis et curcuma longa et un agent antiviral, en tant que principes actifs, destinée à prévenir ou traiter une maladie du foie
WO2021080129A1 (fr) Composition pour renforcer la barrière cutanée et soulager la dermatite atopique, comprenant de l'hydrangénol ou de la phyllodulcine en tant que principe actif
WO2022211396A1 (fr) Composition pharmaceutique incluant un extrait de salvia plebeia r. br. ou un composé dérivé de celui-ci en tant que principe actif pour la prévention ou le traitement de la dystrophie musculaire
WO2017018791A1 (fr) Extrait de fruit de ginseng contenant un ingrédient fonctionnel préventif contre les dommages hépatiques dus à l'alcool et procédé de préparation de celui-ci
WO2016093613A2 (fr) Composition pour la prévention ou le traitement d'une perte de poids anormale, contenant un extrait de pelure de mandarine satsuma
WO2023027317A1 (fr) Composition pour le traitement de maladies liées à la perte musculaire comprenant des exosomes dérivés de cellules souches mésenchymateuses de l'amygdale
WO2010077093A2 (fr) Composition favorisant la croissance des cheveux ou empêchant la perte de cheveux comprenant de l'érythropoïétine
US20210346455A1 (en) Pharmaceutical composition comprising purple corn extract for prevention or treatment of skin disease
WO2021091164A1 (fr) Composition pharmaceutique destinée à prévenir ou traiter l'obésité ou l'allergie comprenant un extrait de rose comme ingrédient actif
WO2021182913A1 (fr) Composition, comprenant un extrait de placenta, pour prévenir ou traiter une maladie hépatique et améliorer la fonction hépatique
WO2021149902A1 (fr) Composition comprenant un extrait de salvia miltiorrhiza comme principe actif servant à la prévention et au traitement de la dépression chez les femmes ménopausées
WO2021033995A1 (fr) Composition comprenant un extrait d'amomum tsaoko pour prévenir, atténuer ou traiter une maladie liée à la sarcopénie
WO2020149538A1 (fr) Composition pharmaceutique comprenant des cellules souches clonales pour la prévention ou le traitement de la dermatite atopique
WO2021070999A1 (fr) Composition destinée à la prévention, à l'amélioration ou au traitement de syndromes métaboliques y compris l'obésité, le diabète, une hyperlipidémie et la stéatose hépatique
WO2018194261A1 (fr) Utilisation thérapeutique de 4'-o-méthyl alpinum isoflavone
WO2022220458A1 (fr) Composition comprenant un extrait de fruit immature d'aurantii comme ingrédient actif pour la prévention ou le traitement d'un symptôme de la climatère masculin
WO2021033994A1 (fr) Composition comprenant un extrait de salvia miltiorrhiza ou de paeonia lactiflora utilisé comme principe actif pour la prévention ou le traitement d'un trouble du métabolisme des lipides
WO2024080435A1 (fr) Composition comprenant du farnésol pour favoriser la prolifération et la différenciation de cellules souches musculaires
WO2021071321A1 (fr) Composition de prévention ou de traitement de maladie neurodégénératives, contenant un extrait d'un mélange de plantes composé de flos genkwae, de racine de clématite et de rhizome de gastrodia

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22781515

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22781515

Country of ref document: EP

Kind code of ref document: A1